Moving to the Core: Spatiotemporal analysis of forkhead Box O (FOXO) and nuclear factor-κB (NF-κB) nuclear translocation

Traffic

Volumn 14, Issue 3, 2013, Pages 247-258

  Zanella, Fabian ^a   dos Santos, Nuno R ^b   Link, Wolfgang ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF ALGARVE   (Portugal)

Author keywords

Cancer; FOXO; high content screening; inflammation; NF B; nuclear translocation; oscillation

Indexed keywords

ENZYME INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; NUCLEOPORIN; TRANSCRIPTION FACTOR FOXO;

APOPTOSIS; CELL MIGRATION; CELLULAR DISTRIBUTION; CYTOPLASM; ENZYME ACTIVATION; GENETIC SCREENING; HUMAN; IMAGE ANALYSIS; NUCLEOCYTOPLASMIC TRANSPORT; PRIORITY JOURNAL; PROTEIN PROCESSING; REVIEW; SIGNAL TRANSDUCTION;

ACTIVE TRANSPORT, CELL NUCLEUS; ANIMALS; CELL NUCLEUS; FORKHEAD TRANSCRIPTION FACTORS; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; MICROSCOPY, FLUORESCENCE; NF-KAPPA B; PROTEIN TRANSPORT;

EID: 84873424232     PISSN: 13989219     EISSN: 16000854     Source Type: Journal    
DOI: 10.1111/tra.12034     Document Type: Review

References (121)

1. Hung MC, Link W. Protein localization in disease and therapy. J Cell Sci 2011;124:3381-3392.
2. Field MC, Dacks JB. First and last ancestors: reconstructing evolution of the endomembrane system with ESCRTs, vesicle coat proteins, and nuclear pore complexes. Curr Opin Cell Biol 2009;21:4-13.
3. Strambio-De-Castillia C, Niepel M, Rout MP. The nuclear pore complex: bridging nuclear transport and gene regulation. Nat Rev Mol Cell Biol 2010;11:490-501.
4. Wente SR, Rout MP. The nuclear pore complex and nuclear transport. Cold Spring Harb Perspect Biol 2010;2:a000562.
5. Hoelz A, Debler EW, Blobel G. The structure of the nuclear pore complex. Annu Rev Biochem 2011;80:613-643.
6. Gorlich D, Kutay U. Transport between the cell nucleus and the cytoplasm. Annu Rev Cell Dev Biol 1999;15:607-660.
7. Mattaj IW, Englmeier L. Nucleocytoplasmic transport: the soluble phase. Annu Rev Biochem 1998;67:265-306.
8. Strom AC, Weis K. Importin-beta-like nuclear transport receptors. Genome Biol 2001;2:REVIEWS3008.
9. Turner JG, Dawson J, Sullivan DM. Nuclear export of proteins and drug resistance in cancer. Biochem Pharmacol 2012;83:1021-1032.
10. Poon IK, Jans DA. Regulation of nuclear transport: central role in development and transformation? Traffic 2005;6:173-186.
11. Kau TR, Way JC, Silver PA. Nuclear transport and cancer: from mechanism to intervention. Nat Rev Cancer 2004;4:106-117.
12. Chahine MN, Pierce GN. Therapeutic targeting of nuclear protein import in pathological cell conditions. Pharmacol Rev 2009;61:358-372.
13. Terry LJ, Shows EB, Wente SR. Crossing the nuclear envelope: hierarchical regulation of nucleocytoplasmic transport. Science 2007;318:1412-1416.
14. Kim IS, Kim DH, Han SM, Chin MU, Nam HJ, Cho HP, Choi SY, Song BJ, Kim ER, Bae YS, Moon YH. Truncated form of importin alpha identified in breast cancer cell inhibits nuclear import of p53. J Biol Chem 2000;275:23139-23145.
15. Xu S, Powers MA. Nuclear pore proteins and cancer. Semin Cell Dev Biol 2009;20:620-630.
16. Cooper CS, Park M, Blair DG, Tainsky MA, Huebner K, Croce CM, Vande Woude GF. Molecular cloning of a new transforming gene from a chemically transformed human cell line. Nature 1984;311:29-33.
17. Borrow J, Shearman AM, Stanton VP Jr, Becher R, Collins T, Williams AJ, Dube I, Katz F, Kwong YL, Morris C, Ohyashiki K, Toyama K, Rowley J, Housman DE. The t(7;11)(p15;p15) translocation in acute myeloid leukaemia fuses the genes for nucleoporin NUP98 and class I homeoprotein HOXA9. Nat Genet 1996;12:159-167.
18. Nakamura T, Largaespada DA, Lee MP, Johnson LA, Ohyashiki K, Toyama K, Chen SJ, Willman CL, Chen IM, Feinberg AP, Jenkins NA, Copeland NG, Shaughnessy JD Jr. Fusion of the nucleoporin gene NUP98 to HOXA9 by the chromosome translocation t(7;11)(p15;p15) in human myeloid leukaemia. Nat Genet 1996;12:154-158.
19. Fornerod M, Boer J, van Baal S, Jaegle M, von Lindern M, Murti KG, Davis D, Bonten J, Buijs A, Grosveld G. Relocation of the carboxyterminal part of CAN from the nuclear envelope to the nucleus as a result of leukemia-specific chromosome rearrangements. Oncogene 1995;10:1739-1748.
20. McLane LM, Corbett AH. Nuclear localization signals and human disease. IUBMB Life 2009;61:697-706.
21. Rayet B, Gelinas C. Aberrant rel/nfkb genes and activity in human cancer. Oncogene 1999;18:6938-6947.
22. Turner JG, Sullivan DM. CRM1-mediated nuclear export of proteins and drug resistance in cancer. Curr Med Chem 2008;15:2648-2655.
23. Salmena L, Pandolfi PP. Changing venues for tumour suppression: balancing destruction and localization by monoubiquitylation. Nat Rev Cancer 2007;7:409-413.
24. Dansen TB, Burgering BM. Unravelling the tumor-suppressive functions of FOXO proteins. Trends Cell Biol 2008;18:421-429.
25. Faustino RS, Nelson TJ, Terzic A, Perez-Terzic C. Nuclear transport: target for therapy. Clin Pharmacol Ther 2007;81:880-886.
26. Taylor DL. Past, present, and future of high content screening and the field of cellomics. Methods Mol Biol 2007;356:3-18.
27. Zanella F, Lorens JB, Link W. High content screening: seeing is believing. Trends Biotechnol 2010;28:237-245.
28. Hahn K, Toutchkine A. Live-cell fluorescent biosensors for activated signaling proteins. Curr Opin Cell Biol 2002;14:167-172.
29. Tsien RY. Building and breeding molecules to spy on cells and tumors. FEBS Lett 2005;579:927-932.
30. Heydorn A, Lundholt BK, Praestegaard M, Pagliaro L. Protein translocation assays: key tools for accessing new biological information with high-throughput microscopy. Methods Enzymol 2006;414:513-530.
31. Rothbauer U, Zolghadr K, Tillib S, Nowak D, Schermelleh L, Gahl A, Backmann N, Conrath K, Muyldermans S, Cardoso MC, Leonhardt H. Targeting and tracing antigens in live cells with fluorescent nanobodies. Nat Methods 2006;3:887-889.
32. Schmidthals K, Helma J, Zolghadr K, Rothbauer U, Leonhardt H. Novel antibody derivatives for proteome and high-content analysis. Anal Bioanal Chem 2010;397:3203-3208.
33. Wollman R, Stuurman N. High throughput microscopy: from raw images to discoveries. J Cell Sci 2007;120:3715-3722.
34. Zanella F, Rosado A, Blanco F, Henderson BR, Carnero A, Link W. An HTS approach to screen for antagonists of the nuclear export machinery using high content cell-based assays. Assay Drug Dev Technol 2007;5:333-341.
35. Taylor DL. A personal perspective on high-content screening (HCS): from the beginning. J Biomol Screen 2010;15:720-725.
36. Bertelsen M, Sanfridson A. Inflammatory pathway analysis using a high content screening platform. Assay Drug Dev Technol 2005;3:261-271.
37. Giddings AM, Maitra R. A disease-relevant high-content screening assay to identify anti-inflammatory compounds for use in cystic fibrosis. J Biomol Screen 2010;15:1204-1210.
38. Young EW, Pak C, Kahl BS, Yang DT, Callander NS, Miyamoto S, Beebe DJ. Microscale functional cytomics for studying hematologic cancers. Blood 2012;119:e76-e85.
39. Kau TR, Schroeder F, Ramaswamy S, Wojciechowski CL, Zhao JJ, Roberts TM, Clardy J, Sellers WR, Silver PA. A chemical genetic screen identifies inhibitors of regulated nuclear export of a Forkhead transcription factor in PTEN-deficient tumor cells. Cancer Cell 2003;4:463-476.
40. Link W, Oyarzabal J, Serelde BG, Albarran MI, Rabal O, Cebria A, Alfonso P, Fominaya J, Renner O, Peregrina S, Soilan D, Ceballos PA, Hernandez AI, Lorenzo M, Pevarello P, et al. Chemical interrogation of FOXO3a nuclear translocation identifies potent and selective inhibitors of phosphoinositide 3-kinases. J Biol Chem 2009;284:28392-28400.
41. Zanella F, Rosado A, Garcia B, Carnero A, Link W. Chemical genetic analysis of FOXO nuclear-cytoplasmic shuttling by using image-based cell screening. Chembiochem 2008;9:2229-2237.
42. Zanella F, Renner O, Garcia B, Callejas S, Dopazo A, Peregrina S, Carnero A, Link W. Human TRIB2 is a repressor of FOXO that contributes to the malignant phenotype of melanoma cells. Oncogene 2010;29:2973-2982.
43. Zanella F, Rosado A, Garcia B, Carnero A, Link W. Using multiplexed regulation of luciferase activity and GFP translocation to screen for FOXO modulators. BMC Cell Biol 2009;10:14.
44. Mattila J, Kallijarvi J, Puig O. RNAi screening for kinases and phosphatases identifies FoxO regulators. Proc Natl Acad Sci USA 2008;105:14873-14878.
45. Wolff M, Kredel S, Haasen D, Wiedenmann J, Nienhaus GU, Kistler B, Oswald F, Heilker R. High content screening of CXCR2-dependent signalling pathways. Comb Chem High Throughput Screen 2010;13:3-15.
46. Xu GW, Mawji IA, Macrae CJ, Koch CA, Datti A, Wrana JL, Dennis JW, Schimmer AD. A high-content chemical screen identifies ellipticine as a modulator of p53 nuclear localization. Apoptosis 2008;13:413-422.
47. Dull A, Goncharova E, Hager G, McMahon JB. Development of an image analysis screen for estrogen receptor alpha (ERalpha) ligands through measurement of nuclear translocation dynamics. J Steroid Biochem Mol Biol 2010;122:341-351.
48. Trask OJ Jr, Baker A, Williams RG, Nickischer D, Kandasamy R, Laethem C, Johnston PA, Johnston PA. Assay development and case history of a 32K-biased library high-content MK2-EGFP translocation screen to identify p38 mitogen-activated protein kinase inhibitors on the ArrayScan 3.1 imaging platform. Methods Enzymol 2006;414:419-439.
49. Trask OJ, Nickischer D, Burton A, Williams RG, Kandasamy RA, Johnston PA, Johnston PA. High-throughput automated confocal microscopy imaging screen of a kinase-focused library to identify p38 mitogen-activated protein kinase inhibitors using the GE InCell 3000 analyzer. Methods Mol Biol 2009;565:159-186.
50. Granas C, Lundholt BK, Loechel F, Pedersen HC, Bjorn SP, Linde V, Krogh-Jensen C, Nielsen EM, Praestegaard M, Nielsen SJ. Identification of RAS-mitogen-activated protein kinase signaling pathway modulators in an ERF1 redistribution screen. J Biomol Screen 2006;11:423-434.
51. Lundholt BK, Linde V, Loechel F, Pedersen HC, Moller S, Praestegaard M, Mikkelsen I, Scudder K, Bjorn SP, Heide M, Arkhammar PO, Terry R, Nielsen SJ. Identification of Akt pathway inhibitors using redistribution screening on the FLIPR and the IN Cell 3000 analyzer. J Biomol Screen 2005;10:20-29.
52. Wolff M, Haasen D, Merk S, Kroner M, Maier U, Bordel S, Wiedenmann J, Nienhaus GU, Valler M, Heilker R. Automated high content screening for phosphoinositide 3 kinase inhibition using an AKT 1 redistribution assay. Comb Chem High Throughput Screen 2006;9:339-350.
53. Wolff M, Kauschke SG, Schmidt S, Heilker R. Activation and translocation of glucokinase in rat primary hepatocytes monitored by high content image analysis. J Biomol Screen 2008;13:837-846.
54. Brunet A, Bonni A, Zigmond MJ, Lin MZ, Juo P, Hu LS, Anderson MJ, Arden KC, Blenis J, Greenberg ME. Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell 1999;96:857-868.
55. Calnan DR, Brunet A. The FoxO code. Oncogene 2008;27:2276-2288.
56. Greer EL, Brunet A. FOXO transcription factors at the interface between longevity and tumor suppression. Oncogene 2005;24:7410-7425.
57. Paik JH, Kollipara R, Chu G, Ji H, Xiao Y, Ding Z, Miao L, Tothova Z, Horner JW, Carrasco DR, Jiang S, Gilliland DG, Chin L, Wong WH, Castrillon DH, et al. FoxOs are lineage-restricted redundant tumor suppressors and regulate endothelial cell homeostasis. Cell 2007;128:309-323.
58. Myatt SS, Lam EW. The emerging roles of forkhead box (Fox) proteins in cancer. Nat Rev Cancer 2007;7:847-859.
59. Engelman JA. Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer 2009;9:550-562.
60. Ronnebaum SM, Patterson C. The FoxO family in cardiac function and dysfunction. Annu Rev Physiol 2010;72:81-94.
61. Skurk C, Izumiya Y, Maatz H, Razeghi P, Shiojima I, Sandri M, Sato K, Zeng L, Schiekofer S, Pimentel D, Lecker S, Taegtmeyer H, Goldberg AL, Walsh K. The FOXO3a transcription factor regulates cardiac myocyte size downstream of AKT signaling. J Biol Chem 2005;280:20814-20823.
62. Brunet A, Sweeney LB, Sturgill JF, Chua KF, Greer PL, Lin Y, Tran H, Ross SE, Mostoslavsky R, Cohen HY, Hu LS, Cheng HL, Jedrychowski MP, Gygi SP, Sinclair DA, et al. Stress-dependent regulation of FOXO transcription factors by the SIRT1 deacetylase. Science 2004;303:2011-2015.
63. Essers MA, Weijzen S, de Vries-Smits AM, Saarloos I, de Ruiter ND, Bos JL, Burgering BM. FOXO transcription factor activation by oxidative stress mediated by the small GTPase Ral and JNK. EMBO J 2004;23:4802-4812.
64. Lehtinen MK, Yuan Z, Boag PR, Yang Y, Villen J, Becker EB, DiBacco S, de la Iglesia N, Gygi S, Blackwell TK, Bonni A. A conserved MST-FOXO signaling pathway mediates oxidative-stress responses and extends life span. Cell 2006;125:987-1001.
65. Ding GJ, Fischer PA, Boltz RC, Schmidt JA, Colaianne JJ, Gough A, Rubin RA, Miller DK. Characterization and quantitation of NF-kappaB nuclear translocation induced by interleukin-1 and tumor necrosis factor-alpha. Development and use of a high capacity fluorescence cytometric system. J Biol Chem 1998;273:28897-28905.
66. Hannon MM, Lohan F, Erbilgin Y, Sayitoglu M, O'Hagan K, Mills K, Ozbek U, Keeshan K. Elevated TRIB2 with NOTCH1 activation in paediatric/adult T-ALL. Br J Haematol 2012;158:626-634.
67. Sanda T, Lawton LN, Barrasa MI, Fan ZP, Kohlhammer H, Gutierrez A, Ma W, Tatarek J, Ahn Y, Kelliher MA, Jamieson CH, Staudt LM, Young RA, Look AT. Core Transcriptional Regulatory Circuit Controlled by the TAL1 Complex in Human T Cell Acute Lymphoblastic Leukemia. Cancer Cell 2012;22:209-221.
68. Grandinetti KB, Stevens TA, Ha S, Salamone RJ, Walker JR, Zhang J, Agarwalla S, Tenen DG, Peters EC, Reddy VA. Overexpression of TRIB2 in human lung cancers contributes to tumorigenesis through downregulation of C/EBPalpha. Oncogene 2011;30:3328-3335.
69. Keeshan K, Bailis W, Dedhia PH, Vega ME, Shestova O, Xu L, Toscano K, Uljon SN, Blacklow SC, Pear WS. Transformation by Tribbles homolog 2 (Trib2) requires both the Trib2 kinase domain and COP1 binding. Blood 2010;116:4948-4957.
70. Keeshan K, He Y, Wouters BJ, Shestova O, Xu L, Sai H, Rodriguez CG, Maillard I, Tobias JW, Valk P, Carroll M, Aster JC, Delwel R, Pear WS. Tribbles homolog 2 inactivates C/EBPalpha and causes acute myelogenous leukemia. Cancer Cell 2006;10:401-411.
71. Tenbaum SP, Ordonez-Moran P, Puig I, Chicote I, Arques O, Landolfi S, Fernandez Y, Herance JR, Gispert JD, Mendizabal L, Aguilar S, Ramon y Cajal S, Schwartz S Jr, Vivancos A, Espin E, et al. Beta-catenin confers resistance to PI3K and AKT inhibitors and subverts FOXO3a to promote metastasis in colon cancer. Nat Med 2012;18:892-901.
72. Frescas D, Valenti L, Accili D. Nuclear trapping of the forkhead transcription factor FoxO1 via Sirt-dependent deacetylation promotes expression of glucogenetic genes. J Biol Chem 2005;280:20589-20595.
73. Schroeder FC, Kau TR, Silver PA, Clardy J. The psammaplysenes, specific inhibitors of FOXO1a nuclear export. J Nat Prod 2005;68:574-576.
74. Tsai WC, Bhattacharyya N, Han LY, Hanover JA, Rechler MM. Insulin inhibition of transcription stimulated by the forkhead protein Foxo1 is not solely due to nuclear exclusion. Endocrinology 2003;144:5615-5622.
75. van der Horst A, de Vries-Smits AM, Brenkman AB, van Triest MH, van den Broek N, Colland F, Maurice MM, Burgering BM. FOXO4 transcriptional activity is regulated by monoubiquitination and USP7/HAUSP. Nat Cell Biol 2006;8:1064-1073.
76. Brenkman AB, de Keizer PL, van den Broek NJ, van der Groep P, van Diest PJ, van der Horst A, Smits AM, Burgering BM. The peptidyl-isomerase Pin1 regulates p27kip1 expression through inhibition of Forkhead box O tumor suppressors. Cancer Res 2008;68:7597-7605.
77. Housley MP, Udeshi ND, Rodgers JT, Shabanowitz J, Puigserver P, Hunt DF, Hart GW. A PGC-1alpha-O-GlcNAc transferase complex regulates FoxO transcription factor activity in response to glucose. J Biol Chem 2009;284:5148-5157.
78. Housley MP, Rodgers JT, Udeshi ND, Kelly TJ, Shabanowitz J, Hunt DF, Puigserver P, Hart GW. O-GlcNAc regulates FoxO activation in response to glucose. J Biol Chem 2008;283:16283-16292.
79. Birbach A, Gold P, Binder BR, Hofer E, de Martin R, Schmid JA. Signaling molecules of the NF-kappa B pathway shuttle constitutively between cytoplasm and nucleus. J Biol Chem 2002;277:10842-10851.
80. Ghosh S, Karin M. Missing pieces in the NF-kappaB puzzle. Cell 2002;109:S81-96.
81. Hayden MS, Ghosh S. Shared principles in NF-kappaB signaling. Cell 2008;132:344-362.
82. Vallabhapurapu S, Karin M. Regulation and function of NF-kappaB transcription factors in the immune system. Annu Rev Immunol 2009;27:693-733.
83. Hayden MS, Ghosh S. Signaling to NF-kappaB. Genes Dev 2004;18:2195-2224.
84. Karin M, Ben-Neriah Y. Phosphorylation meets ubiquitination: the control of NF-[kappa]B activity. Annu Rev Immunol 2000;18:621-663.
85. Saccani S, Marazzi I, Beg AA, Natoli G. Degradation of promoter-bound p65/RelA is essential for the prompt termination of the nuclear factor kappaB response. J Exp Med 2004;200:107-113.
86. Tanaka T, Grusby MJ, Kaisho T. PDLIM2-mediated termination of transcription factor NF-kappaB activation by intranuclear sequestration and degradation of the p65 subunit. Nat Immunol 2007;8:584-591.
87. Lee EG, Boone DL, Chai S, Libby SL, Chien M, Lodolce JP, Ma A. Failure to regulate TNF-induced NF-kappaB and cell death responses in A20-deficient mice. Science 2000;289:2350-2354.
88. Shembade N, Ma A, Harhaj EW. Inhibition of NF-kappaB signaling by A20 through disruption of ubiquitin enzyme complexes. Science 2010;327:1135-1139.
89. Wertz IE, O'Rourke KM, Zhou H, Eby M, Aravind L, Seshagiri S, Wu P, Wiesmann C, Baker R, Boone DL, Ma A, Koonin EV, Dixit VM. De-ubiquitination and ubiquitin ligase domains of A20 downregulate NF-kappaB signalling. Nature 2004;430:694-699.
90. Sun SC. Non-canonical NF-kappaB signaling pathway. Cell Res 2011;21:71-85.
91. Basak S, Kim H, Kearns JD, Tergaonkar V, O'Dea E, Werner SL, Benedict CA, Ware CF, Ghosh G, Verma IM, Hoffmann A. A fourth IkappaB protein within the NF-kappaB signaling module. Cell 2007;128:369-381.
92. Dejardin E, Droin NM, Delhase M, Haas E, Cao Y, Makris C, Li ZW, Karin M, Ware CF, Green DR. The lymphotoxin-beta receptor induces different patterns of gene expression via two NF-kappaB pathways. Immunity 2002;17:525-535.
93. Anest V, Hanson JL, Cogswell PC, Steinbrecher KA, Strahl BD, Baldwin AS. A nucleosomal function for IkappaB kinase-alpha in NF-kappaB-dependent gene expression. Nature 2003;423:659-663.
94. Liao G, Sun SC. Regulation of NF-kappaB2/p100 processing by its nuclear shuttling. Oncogene 2003;22:4868-4874.
95. Tsuchiya Y, Asano T, Nakayama K, Kato T Jr, Karin M, Kamata H. Nuclear IKKbeta is an adaptor protein for IkappaBalpha ubiquitination and degradation in UV-induced NF-kappaB activation. Mol Cell 2010;39:570-582.
96. Bartfeld S, Hess S, Bauer B, Machuy N, Ogilvie LA, Schuchhardt J, Meyer TF. High-throughput and single-cell imaging of NF-kappaB oscillations using monoclonal cell lines. BMC Cell Biol 2010;11:21.
97. Hoffmann A, Levchenko A, Scott ML, Baltimore D. The IkappaB-NF-kappaB signaling module: temporal control and selective gene activation. Science 2002;298:1241-1245.
98. Nelson DE, Ihekwaba AEC, Elliott M, Johnson JR, Gibney CA, Foreman BE, Nelson G, See V, Horton CA, Spiller DG, Edwards SW, McDowell HP, Unitt JF, Sullivan E, Grimley R, et al. Oscillations in NF-kappaB signaling control the dynamics of gene expression. Science 2004;306:704-708.
99. Werner SL, Kearns JD, Zadorozhnaya V, Lynch C, O'Dea E, Boldin MP, Ma A, Baltimore D, Hoffmann A. Encoding NF-kappaB temporal control in response to TNF: distinct roles for the negative regulators IkappaBalpha and A20. Genes Dev 2008;22:2093-2101.
100. Bosisio D, Marazzi I, Agresti A, Shimizu N, Bianchi ME, Natoli G. A hyper-dynamic equilibrium between promoter-bound and nucleoplasmic dimers controls NF-kappaB-dependent gene activity. EMBO J 2006;25:798-810.
101. Covert MW, Leung TH, Gaston JE, Baltimore D. Achieving stability of lipopolysaccharide-induced NF-kappaB activation. Science 2005;309:1854-1857.
102. Lee TK, Covert MW. High-throughput, single-cell NF-kappaB dynamics. Curr Opin Genet Dev 2010;20:677-683.
103. Renner F, Schmitz ML. Autoregulatory feedback loops terminating the NF-kappaB response. Trends Biochem Sci 2009;34:128-135.
104. Spiller DG, Wood CD, Rand DA, White MR. Measurement of single-cell dynamics. Nature 2010;465:736-745.
105. Ashall L, Horton CA, Nelson DE, Paszek P, Harper CV, Sillitoe K, Ryan S, Spiller DG, Unitt JF, Broomhead DS, Kell DB, Rand DA, See V, White MR. Pulsatile stimulation determines timing and specificity of NF-kappaB-dependent transcription. Science 2009;324:242-246.
106. Tay S, Hughey JJ, Lee TK, Lipniacki T, Quake SR, Covert MW. Single-cell NF-kappaB dynamics reveal digital activation and analogue information processing. Nature 2010;466:267-271.
107. Perkins ND. The diverse and complex roles of NF-kappaB subunits in cancer. Nat Rev Cancer 2012;12:121-132.
108. Lin YZ, Yao SY, Veach RA, Torgerson TR, Hawiger J. Inhibition of nuclear translocation of transcription factor NF-kappa B by a synthetic peptide containing a cell membrane-permeable motif and nuclear localization sequence. J Biol Chem 1995;270:14255-14258.
109. Mabuchi S, Ohmichi M, Nishio Y, Hayasaka T, Kimura A, Ohta T, Kawagoe J, Takahashi K, Yada-Hashimoto N, Seino-Noda H, Sakata M, Motoyama T, Kurachi H, Testa JR, Tasaka K, et al. Inhibition of inhibitor of nuclear factor-kappaB phosphorylation increases the efficacy of paclitaxel in in vitro and in vivo ovarian cancer models. Clin Cancer Res 2004;10:7645-7654.
110. Torgerson TR, Colosia AD, Donahue JP, Lin YZ, Hawiger J. Regulation of NF-kappa B, AP-1, NFAT, and STAT1 nuclear import in T lymphocytes by noninvasive delivery of peptide carrying the nuclear localization sequence of NF-kappa B p50. J Immunol 1998;161:6084-6092.
111. Xu Y, Fang F, St Clair DK, Sompol P, Josson S, St Clair WH. SN52, a novel nuclear factor-kappaB inhibitor, blocks nuclear import of RelB:p52 dimer and sensitizes prostate cancer cells to ionizing radiation. Mol Cancer Ther 2008;7:2367-2376.
112. Mineva ND, Wang X, Yang S, Ying H, Xiao ZX, Holick MF, Sonenshein GE. Inhibition of RelB by 1, 25-dihydroxyvitamin D3 promotes sensitivity of breast cancer cells to radiation. J Cell Physiol 2009;220:593-599.
113. dos Santos NR, Williame M, Gachet S, Cormier F, Janin A, Weih D, Weih F, Ghysdael J. RelB-dependent stromal cells promote T-cell leukemogenesis. PLoS One 2008;3:e2555.
114. Kwon YJ, Genovesio A, Youl KN, Hi CK, Jung S, David-Watine B, Nehrbass U, Emans N. High-content classification of nucleocytoplasmic import or export inhibitors. J Biomol Screen 2007;12:621-627.
115. Borchert KM, Sells Galvin RJ, Hale LV, Trask OJ, Nickischer DR, Houck KA. Screening for activators of the wingless type/Frizzled pathway by automated fluorescent microscopy. Methods Enzymol 2006;414:140-150.
116. Atwal RS, Desmond CR, Caron N, Maiuri T, Xia J, Sipione S, Truant R. Kinase inhibitors modulate huntingtin cell localization and toxicity. Nat Chem Biol 2011;7:453-460.
117. Vijayakumar RS, Lin Y, Shia KS, Yeh YN, Hsieh WP, Hsiao WC, Chang CP, Chao YS, Hung MS. Induction of fatty acid oxidation resists weight gain, ameliorates hepatic steatosis and reduces cardiometabolic risk factors. Int J Obes (Lond) 2012;36:999-1006.
118. Li H, Chen T, Cottrell J, Wang H. Nuclear translocation of adenoviral-enhanced yellow fluorescent protein-tagged-human constitutive androstane receptor (hCAR): a novel tool for screening hCAR activators in human primary hepatocytes. Drug Metab Dispos 2009;37:1098-1106.
119. Granda TG, Cebrian D, Martinez S, Anguita PV, Lopez EC, Link W, Merino T, Pastor J, Serelde BG, Peregrina S, Palacios I, Albarran MI, Cebria A, Lorenzo M, Alonso P, et al. Biological characterization of ETP-46321 a selective and efficacious inhibitor of phosphoinositide-3-kinases. Investigational New Drugs May 2012, DOI 10.1007/s10637-012-9835-5.
120. Martinez GS, Hernandez AI, Varela C, Rodriguez-Aristegui S, Lorenzo M, Rodriguez A, Rivero V, Martin JI, Saluste CG, Ramos-Lima F, Cendon E, Cebrian D, Aguirre E, Gomez-Casero E, Albarran M, et al. Identification of ETP-46321, a potent and orally bioavailable PI3K alpha, delta inhibitor. Bioorg Med Chem Lett 2012;22:3460-3466.
121. Gamble C, McIntosh K, Scott R, Ho KH, Plevin R, Paul A. Inhibitory kappa B Kinases as targets for pharmacological regulation. Br J Pharmacol 2012;165:802-819.